Paris, France – Inato, a technology platform that connects global pharmaceutical companies with research sites around the world, announced it has raised $20 million in a Series A funding round led by Cathay Innovation and Top Harvest Capital. Obvious Ventures also joined the round.

The funding will allow Inato to accelerate its mission of bringing clinical trials to every patient regardless of who they are or where they live. Currently, only 5% of sites run 70% of clinical trials, leaving many without access to these trials. By expanding access and creating a platform that connects global pharmaceutical companies with a broader range of research sites while ensuring reliable high performance, Inato is making clinical trials more accessible, efficient, and inclusive.

“At Inato, we envision a world where it’s so easy to find and apply for the right trial that the other 95% of sites—often community-based research sites—can play a bigger role and accelerate research," said Kourosh Davarpanah co-founder and CEO at Inato. "By working together to bring trial access into communities across the globe we can develop treatments that are safe and effective for everyone."